Abbott. Where Abbott is the Other Party and Neurocrine terminated […***…] pursuant to 11.4(a), the provisions of Section 11.2(b) shall apply provided however, that if this Agreement is terminated only with respect to […***…], the provisions of Section 11.2(b) shall apply mutatis mutandis to termination by Neurocrine pursuant to this Section but only with respect to […***…].
Abbott. In the event Abbott is the Insolvent Party, in addition to any other remedies available to Neurocrine at Law or in equity, Neurocrine may terminate this Agreement and the provisions of Section 11.2(b) shall apply to termination by Neurocrine pursuant to this Section.
Abbott and Iomed shall cooperate fully in estimating and scheduling production for the first firm order to be placed by Iomed. The first firm order shall cover a period of three (3) consecutive calendar months. Thereafter, firm orders shall be placed monthly and shall cover the next succeeding third month. At the time Iomed places its firm monthly orders, Iomed shall provide to Abbott Iomed's estimate of its monthly requirements for the next succeeding nine (9) calendar month 7 8 period. It is the intent that at all times Abbott shall have in hand firm monthly orders covering the current three (3) calendar month period and Iomed's estimates of its monthly requirements for the next succeeding nine (9) calendar month period.
Abbott. Abbott shall have full responsibility and discretion in conducting, including settling, any Tax Contest involving (x) any Tax for which it is responsible under Section 2.01(a), (y) any Covered Transaction Tax for which Hospira is responsible under Section 3.01(b), except as provided in paragraph (iii), below and (z) any Transition Period Tax for which Hospira is responsible under Section 3.02. Abbott shall consult in good faith with Hospira in connection with any Tax Contest described in clauses (y) or (z) of this Section 2.06(b)(ii).
Abbott. Metabasis hereby agrees that Sicor shall have the sole right, in its sole discretion, to initiate and control negotiations with Xxxxxx Laboratories, Inc. and its Affiliates (collectively, "Abbott") regarding granting Abbott a license to the Licensed Technology. Metabasis shall not have the right to grant to Abbott a license to the Licensed Technology, or to participate in or influence any negotiations between Sicor and Abbott, without the prior written consent of Sicor.
Abbott. 2.2.1 Abbott will carry out a maximum of xxx xxfferent trials using its Meltrex(TM) Technology, focusing on [**]
2.2.2 Abbott will carry out preliminary stability testing of the Meltrex(TM) formulations at [**]
2.2.3 In parallel with the above steps, Abbott will also perform process analysis of the Meltrex(TM) formulations [**]
Abbott. 2.2.1 Abbott will manufacture two (2) batches of Bulk Product under GMP conditions for human use including mixing of raw materials and extrusion.
2.2.2 In parallel with the above step 2.2.1, Abbott will also perform [**]
2.2.3 Abbott will carry out short term stability testing of the two (2) batches of Bulk Product obtained under step 2.2.1 above [**] according to ICH conditions in bulk container packaging material. [**]
Abbott. 2.2.1 Abbott will manufacture [**] Bulk Product, xx xxe maximum amount thax xxx be manufactured out of the remainder material, to be used for technical assessment and further manufacturing trials including mixing of raw materials and extrusion.
2.2.2 In parallel with the above step 2.2.1, Abbott will also perform process analysis of the Meltrex(TM) formulaxxxxx for [**]. ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.
Abbott. 2.2.1 Abbott will carry out process development of the selecxxx xxrmulatiox xx Bulk Product on its [**] in accordance with the Development Protocol agreed between the parties and attached hereto as Appendix A.
2.2.2 Abbott will provide Barrier, or its nominee, with samples (approximaxxxx [**] of Bulk Product resulting from this process development programme ("mock NDA lot") for Barrier, or its nominee, to carry out further milling and tabletting experiments.
2.2.3 Abbott will then manufacture six (6) batches of Bulk Product using txx [**], each batch being [**] kg, and will supply these six (6) batches to Barrier, or its nominee, for milling and tabletting into Finished product.
2.2.4 Abbott will carry out in process controls and analytical characterizxxxxx appropriate for NDA batches. Abbott will take forensic samples for the FDA and will provide xxxx samples to Barrier or its nominee. ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.
2.2.5 Abbott will provide Barrier with copies of executed batch records, xncluding all associated documentation such as test results and any deviation reports.
2.2.6 Abbott will provide Barrier with a final development report as soon xx reasonably possible after completing the development programme.
Abbott. ICOS hereby grants to Abbott a [ * ] license under the ------ ICOS Product Know How and ICOS Product Patent Rights to make, have made, use, sell, offer to sell and import [ * ].